Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with Homologous Recombination Deficient (HRD) negative advanced ovarian cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki z nowo zdiagnozowanym zaawansowanym rakiem nabłonkowym jajnika, jajowodu lub otrzewnej (stopień III/IV wg FIGO), potwierdzonym histologicznie.
- •Dostarczenie próbki guza z poprzednich badań (próbka utrwalona formaliną i zatopiona w parafinie).
- •Pacjentki, które zakończyły od 6 do 8 cykli chemioterapii opartej na platynie jako pierwszym leczeniu, przed rozpoczęciem badania.
- •Pacjentki, które otrzymały co najmniej 3 cykle Bevacizumabu w połączeniu z ostatnimi 3 cyklami chemioterapii przed rozpoczęciem badania.
- •Pacjentki po operacji usunięcia guza lub z chorobą nieoperacyjną.
- •Pacjentki z chorobą, która nie postępowała po zakończeniu wstępnego leczenia.
- •Guzy pacjentek z niedoborem rekombinacji homoloogicznej (HRD-negatywne).
✗ Disqualifies
- •Pacjentki z guzami nienabłonkowymi, guzami granicznymi lub guzami nabłonkowymi niskiego stopnia złośliwości.
- •Pacjentki z historią choroby płuc (niezakaźne zapalenie płuc/śródmiąższowe choroby płuc) wymagającej leczenia sterydami lub dodatkowego tlenu, lub z obecnym zapaleniem płuc.
- •Pacjentki z niezgojonymi ranami, aktywnymi owrzodzeniami lub złamaniami kości.
- •Pacjentki z objawami niedrożności jelit.
- •Pacjentki, które wcześniej przyjmowały terapie ukierunkowane na receptor FRα lub jakiekolwiek koniugaty lek-przeciwciało skierowane przeciwko TOP1.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (186)
Research Site
Tampa, United States
Research Site
Baltimore, United States
Research Site
Billings, United States
Research Site
Cleveland, United States
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Capital Federal, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Córdoba, Argentina
Research Site
Córdoba, Argentina
Research Site
Rosario, Argentina
Research Site
Salta, Argentina
Research Site
Santa Fe, Argentina
Research Site
Viedma, Argentina
Research Site
Auchenflower, Australia
Research Site
Benowa, Australia
Research Site
Hobart, Australia
Research Site
Kingswood, Australia
Research Site
Nedlands, Australia
Research Site
Port Macquarie, Australia
Research Site
Randwick, Australia
Research Site
Richmond, Australia
Research Site
Toorak Gardens, Australia
Research Site
Wollongong, Australia
Research Site
Fortaleza, Brazil
Research Site
Itajaí, Brazil
Research Site
Jaú, Brazil
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Dobrich, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Shumen, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Toronto, Canada
Research Site
Montreal, Canada
Research Site
Santiago, Chile
Research Site
Santiago, Chile
Research Site
Temuco, Chile
Research Site
Viña del Mar, Chile
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Binzhou Shi, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Haikou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Huangpu District, China
Research Site
Jinan, China
Research Site
Jinan, China
Research Site
Linyi, China
Research Site
Luzhou, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Nanjing, China
Research Site
Neijiang, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shenzhen, China
Research Site
Shijiazhuang, China
Research Site
Suzhou, China
Research Site
Taiyuan, China
Research Site
Weifang, China
Research Site
Wenzhou, China
Research Site
Wuhan, China
Research Site
Xinxiang, China
Research Site
Xuzhou, China
Research Site
Bogotá, Colombia
Research Site
Bogotá, Colombia
Research Site
Medellín, Colombia
Research Site
Pasto, Colombia
Research Site
Berlin, Germany
Research Site
Bonn, Germany
Research Site
Hanover, Germany
Research Site
Wiesbaden, Germany
Research Site
Athens, Greece
Research Site
Pátrai, Greece
Research Site
Ansārinagar, India
Research Site
Bhubaneswar, India
Research Site
Hyderabad, India
Research Site
Mumbai, India
Research Site
Mumbai, India
Research Site
Nagpur, India
Research Site
Nashik, India
Research Site
New Delhi, India
Research Site
Pune, India
Research Site
Thiruvananthapuram, India
Research Site
Hadera, Israel
Research Site
Haifa, Israel
Research Site
Haifa, Israel
Research Site
Holon, Israel
Research Site
Jerusalem, Israel
Research Site
Kfar Saba, Israel
Research Site
Nahariya, Israel
Research Site
Tel Aviv, Israel
Research Site
Florence, Italy
Research Site
Genova, Italy
Research Site
Fukushima, Japan
Research Site
Ginowan-shi, Japan
Research Site
Hidaka-shi, Japan
Research Site
Isehara-shi, Japan
Research Site
Kashiwa-shi, Japan
Research Site
Kawasaki-shi, Japan
Research Site
Kobe, Japan
Research Site
Kōtoku, Japan
Research Site
Kurume-shi, Japan
Research Site
Kyoto, Japan
Research Site
Minatoku, Japan
Research Site
Nagoya, Japan
Research Site
Nagoya, Japan
Research Site
Niigata, Japan
Research Site
Osaka, Japan
Research Site
Osaka, Japan
Research Site
Ota-shi, Japan
Research Site
Sagamihara-shi, Japan
Research Site
Sapporo, Japan
Research Site
Sapporo, Japan
Research Site
Sendai, Japan
Research Site
Shinjuku-ku, Japan
Research Site
Shiwa-gun, Japan
Research Site
Suita, Japan
Research Site
Sunto-gun, Japan
Research Site
Toon-Shi, Japan
Research Site
Tsu, Japan
Research Site
Yokohama, Japan
Research Site
Yokohama, Japan
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuala Selangor, Malaysia
Research Site
Kuala Selangor, Malaysia
Research Site
Petaling Jaya, Malaysia
Research Site
Arequipa, Peru
Research Site
Lima, Peru
Research Site
Lima, Peru
Research Site
Lima, Peru
Research Site
Wanchac, Peru
Research Site
Cebu, Philippines
Research Site
City of Muntinlupa, Philippines
Research Site
Quezon, Philippines
Research Site
Trenčín, Slovakia
Research Site
Ljubljana, Slovenia
Research Site
Busan, South Korea
Research Site
Daegu, South Korea
Research Site
Goyang-si, South Korea
Research Site
Gyeonggi-do, South Korea
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Yangsan, South Korea
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Kaohsiung City, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
New Taipei City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.